Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Elizabeth L. Hougen sold 4,000 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $57.00, for a total transaction of $228,000.00. Following the sale, the senior vice president now directly owns 14,392 shares in the company, valued at $820,344. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up $0.08 during trading hours on Wednesday, hitting $52.54. 901,551 shares of the company’s stock traded hands, compared to its average volume of 1,461,892. Ionis Pharmaceuticals, Inc. has a 12-month low of $37.26 and a 12-month high of $65.51. The firm has a market capitalization of $6,520.00, a P/E ratio of 348.40 and a beta of 2.85. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

Several large investors have recently added to or reduced their stakes in IONS. Vanguard Group Inc. grew its stake in shares of Ionis Pharmaceuticals by 4.4% in the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after acquiring an additional 417,364 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Ionis Pharmaceuticals by 33.0% in the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock valued at $58,027,000 after acquiring an additional 284,266 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Ionis Pharmaceuticals by 40.2% in the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after acquiring an additional 281,733 shares in the last quarter. BlackRock Inc. grew its stake in shares of Ionis Pharmaceuticals by 4.0% in the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock valued at $347,135,000 after acquiring an additional 264,179 shares in the last quarter. Finally, Smith Asset Management Group LP acquired a new position in shares of Ionis Pharmaceuticals in the second quarter valued at about $11,394,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Several analysts have issued reports on IONS shares. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Stifel Nicolaus upped their price target on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Jefferies Group reaffirmed an “underperform” rating and set a $18.00 price target (up from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. BMO Capital Markets upped their price target on shares of Ionis Pharmaceuticals from $67.00 to $69.00 and gave the stock an “outperform” rating in a research report on Monday, August 14th. Finally, Laidlaw reaffirmed a “buy” rating and set a $65.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, August 14th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $50.31.

TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/06/insider-selling-ionis-pharmaceuticals-inc-ions-svp-sells-4000-shares-of-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.